654 related articles for article (PubMed ID: 22248874)
1. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
3. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
Chang AE; Karnell LH; Menck HR
Cancer; 1998 Oct; 83(8):1664-78. PubMed ID: 9781962
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
5. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
6. Primary noncutaneous melanoma.
Wu E; Golitz LE
Clin Lab Med; 2000 Dec; 20(4):731-44. PubMed ID: 11221512
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma.
Law MM; Wong JH
Am Surg; 1994 May; 60(5):362-6. PubMed ID: 8161088
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
9. Incidence of noncutaneous melanomas in the U.S.
McLaughlin CC; Wu XC; Jemal A; Martin HJ; Roche LM; Chen VW
Cancer; 2005 Mar; 103(5):1000-7. PubMed ID: 15651058
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
Tas F; Kurul S; Camlica H; Topuz E
Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
[TBL] [Abstract][Full Text] [Related]
11. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.
Hoersch B; Leiter U; Garbe C
Br J Dermatol; 2006 Oct; 155(4):771-7. PubMed ID: 16965427
[TBL] [Abstract][Full Text] [Related]
12. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic melanoma of unknown primary site].
Laveau F; Picot MC; Dereure O; Guilhou JJ; Guillot B
Ann Dermatol Venereol; 2001 Sep; 128(8-9):893-8. PubMed ID: 11590340
[TBL] [Abstract][Full Text] [Related]
14. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
16. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
19. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
